Arginine and whole brain radiation for brain metastases
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether taking arginine (an amino acid) during whole brain radiation therapy can help people with brain metastases from any type of cancer. It looks at how the treatment affects the body and may improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with brain metastases from any type of cancer.
- You are scheduled to receive whole brain radiation therapy (including a type that avoids the memory area).
- You will not be taking other anti-cancer drugs during the 10 days of radiation (you may take memantine).
- You are 18 years or older.
- You can consent for yourself and are not in the hospital at the start of treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two stereotactic radiation strategies for patients who have intact (not previously radiated) brain metastases that are limited in size. It aims to see which approach works best in controlling the cancer while reducing side effects.
This Phase 2 study tests a treatment plan that combines whole-brain radiation therapy with an additional approach to help people with brain metastases. It aims to improve outcomes while also tracking brain function and memory over time.
This trial tests whether adding tiny gadolinium-containing nanoparticles to standard brain radiation can better control brain metastases from certain cancers. It is for people with tumors that have grown after immunotherapy, are from certain cancers (like melanoma, GI, or HER2+ breast), are cystic, are large, or have come back after prior radiation.
This trial tests a special type of whole-brain radiation that aims to avoid the parts of the brain that control memory. It's for people with many brain tumors (6 or more) that haven't been treated with radiation before.
This study tests a new drug (SHR-A1811) combined with radiation therapy for breast cancer that has spread to the brain. The goal is to see if this combination can help control the brain tumors and possibly improve outcomes.
This trial tests whether adding nitroglycerin (a medicine that widens blood vessels) to standard whole-brain radiation helps improve treatment for lung cancer that has spread to the brain. It is for people with a specific gene change (EGFR mutation) in their cancer.
Hear when a new Metastatic Malignant Neoplasm in the Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.